Navigation Links
Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conference Provide Insight for Future Research
Date:10/20/2009

these trial results afford - a new vantage point to examine what we understand about vaccine design, immunogenicity testing and animal models," added Colonel Kim. "Further research is required to determine if immunological mechanisms mediating protection against HIV may be different from those that control viral replication."

The trial results, first announced by trial collaborators on September 24, 2009, are based on the mITT population, which is the most clinically relevant analysis for this proof-of-concept study. Data from the mITT population, which was monitored by the independent Data and Safety Monitoring Board during its periodic review of the study, include all volunteers who entered the study less seven individuals who were already HIV infected on the first day of vaccination. "Given that you cannot protect someone from an infection that they already have acquired, the modified intent-to-treat analysis excluded these individuals," said Michael.

The detailed study data, which were embargoed for release before the AIDS Vaccine 2009 Conference and The New England Journal of Medicine publication, provide analyses of multiple data subgroups including ITT and per protocol (PP), their definitions and results. Data from the PP population show similar trends (26.2 percent reduction in HIV infection compared to placebo; n=36 vs. n= 50 respectively; p=0.16), though the results did not reach statistical significance due to the exclusion of nearly one-third of volunteers from the analysis and the associated loss of statistical power. For the ITT population, the vaccine regimen reduced infection rates by 26.4 percent compared to placebo (n=56 vs. n=76 respectively; p=0.08).

The U.S. Army would like to thank the more than 16,000 Thai men and women who consented to participate in this trial and the efforts of the Thai Ministry of Public Health. Trial collaborators include the U.S. Army, the Thai Ministry of Public Health, Mahid
'/>"/>

SOURCE U.S. Military HIV Research Program
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Tijuana Newspaper, Zeta Tijuana, Releases Detailed List of Day Care Center Owners and Their Total Earnings; Interchildren, Inc. Calls for Newspaper Boycott
2. Forterus Inc. Treatment Centers Serving Middle-Class; Rapid Growth Detailed in Paul Howarth Interview
3. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
4. The LCA-Vision Full Value Committee Files Detailed Presentations
5. Barriers to Good Asthma Care Detailed
6. Trigger for Stem Cell Differentiation Detailed
7. Texas Detailed Products Today Announced the Second Generation Detail Bag: Skinceuticals Chooses the Detail Bag II Sample Case for all its Pharmaceutical Representatives
8. A map of the worm: First detailed anatomical atlas of C. elegans for use in the lab
9. Biological Link Between BRCA1 and Breast Cancer Detailed
10. Cardiome Pharma Corp. Announces Final Results of Tender Offer
11. Omnicell to Release Third Quarter 2009 Earnings Results on October 22
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2015)... 03, 2015 “ BolehVPN ” was featured ... features the latest and coolest technology products available to consumers. ... conducted the review and shared with viewers how to protect ... these days is on computers and even more so online. ... meet people all over the world. In terms of work, ...
(Date:5/3/2015)... It is not too late to register to take ... of Lissa Anne Been in Arnold, Missouri on May 9, ... to honor her loving memory. It has benefited the renowned Brain ... turned 37, Lissa suffered a brain aneurysm . After two ... This event is designed to serve as a remembrance of her ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 As ... laxity issues of the face, neck and décolleté, ... concept with real potential for the success of ... the ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s Health ... FACS, ACGE, concluded that ThermiGyn’s temperature controlled radio ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... Georgia Tech researchers to decode exactly how a cell ... and reacts //to a broad spectrum of complex biomolecules ... that are capable of targeting some of the most ... used for studying cell communications suffer from significant deficiencies. ...
... by which environmental stimulation decelerates Alzheimer's disease, further ... neurological decline. ,A paper to this effect ... of amyloid angiopathy and A? plaque burden after ... pathways," appears in the2006 August issue of The ...
... August 1 at the annual meeting of the American ... a specific mixture// of electron and x-ray beams that ... of collateral damage in breast cancer patients. Jinsheng Li, ... Cancer Center in Philadelphia developed this specific mixture using ...
... of Cincinnati on skin cancers has revealed that people with ... when they do get //it they are associated with higher ... done at an advanced stage. ,In a ... Hugh Gloster, Dermatologist at University of Cincinnati, he has concluded ...
... York City has discovered that chronic pain occurs as a ... were studying chronic pain at the molecular and cellular level. ... the neurons becomes excited and begin to send signals to ... stimulus is removed the nerves become dormant and there is ...
... patient was discharged for a week after undergoing successful surgery, ... Guoxing, 30, who had not seen his wife and two ... returned home Friday for a week-long visit to his family ... his face is alive and Li has been doing well, ...
Cached Medicine News:Health News:Cell Behavior Better Understood with Nano Probe 2Health News:Cell Behavior Better Understood with Nano Probe 3Health News:Active Life Decelerates Alzheimer's 2Health News:Radiation Cocktail May Reduce Risk of Damage To Other Organs In Breast Cancer 2
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... Timothy E. Morris , chief financial officer  will be ... events are as follows: Mizuho Third Annual ...  The Omni Berkshire Place, New York ...
(Date:5/1/2015)... -- Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) ... results of the Phase 3 Rocket 1 trail of ... to meet its end points, compelling data from the ... studies. An analyst report on AERI that ... analyst summary, valuation, and recommendation can be viewed by ...
(Date:4/30/2015)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the fourth quarter and fiscal year ... fiscal 2015 overview: , Revenues from continuing operations ... over last year,s comparable quarter, and $202.6 million for ... of $0.50 for the fourth quarter, up 194% over ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24
... announced today,that it has begun enrollment of the ... eluting coronary stent clinical trial. Atrium,s,European FIM clinical ... stent system., This First-in-Man trial is a ... CINATRA(TM) voclosporin coated,coronary stent system, which will be ...
... Results for SB-509 in Development for ... 8 Sangamo BioSciences,Inc. (Nasdaq: SGMO ) ... data from its ZFP Therapeutic(TM) program at the ... As,disclosed in an oral presentation entitled, "Evidence of ...
Cached Medicine Technology:Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent 2Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 9
Shandon Laser MicroWriter is a laser labeling system developed specifically for anatomical pathology....
Eberbach's 2800 Series Micro Slide Cabinets provide safe, short-term and long-term, storage of prepared slides which can easily be indexed for retrieval. Cabinets are available in (2) two styles, a U...
Compact storage cabinets for 35 mm slides....
Fisherbrand* Micro Slide Cabinet is made of heavy gauge, reinforced steel....
Medicine Products: